ICER’s Alternative Pricing Models: New Threats to Biopharmaceutical’s Profitability and Innovation

The Institute for Clinical and Economic Review (ICER) has been very responsive to the current public health pandemic, from adjusting their review timelines to assessing COVID-19 impact on drug pricing and patient access. Within a few days of Gilead’s remdesivir gaining emergency approval by the U.S. Food and Drug Administration (FDA), ICER has published an analysis on alternative pricing models for the therapy and other potential treatments for COVID-19. [See full report here]

Heather Lee Whipple, Senior Vice President, Brand Market Access Insights, analyzes ICER’s dramatic shift from QALY to pharma profit metrics, its impact on contracting negotiations, innovation and overall implications for the industry.

Fill out the form below to download the FREE report!

Author
Heather Lee Whipple
Senior Vice President, Health Strategies

Heather Lee is responsible for leading and expanding the brand market access insights capabilities within Health Strategies Insights, the comprehensive market access research and insights portfolio, in order to help life science innovators make…